Table 1.

Change in fatty acid content for the 34 subjects who completed the trial

Median values
Percent of total fatty acid content
Tissue/lipid compartment fatty acid componentBaseline6 moa6.5 mobRelative change baseline to FNA2P (Wilcoxon) for baseline to FNA2c
Erythrocyte PLsN = 34N = 34N = 32N = 32
AA12.810.710.8−16%<0.001
EPA0.402.241.27235%<0.001
DHA2.955.464.7164%<0.001
EPA+DHA:AA ratio0.270.760.56117%<0.001
Plasma PLsN = 34N = 34N = 32N = 32
AA9.98.28.6−11%<0.001
EPA0.542.800.6430%0.0013
DHA2.504.503.3537%<0.001
EPA+DHA:AA ratio0.300.910.4544%<0.001
Plasma TAGsN = 34N = 34N = 31N = 31
AA1.581.441.50−10%0.29
EPA0.181.020.2428%0.017
DHA0.471.940.6761%<0.001
EPA+DHA:AA ratio0.381.970.7349%<0.001
Breast TAGsN = 32N = 32N = 32
AA0.320.346.5%0.47
EPA0.0330.096165%<0.001
DHA0.0730.14742%<0.001
EPA+DHA:AA ratio0.290.5196%<0.001
Breast PLsN = 33N = 33N = 33
AA0.650.572.9%0.54
EPA0.0510.04921%0.30
DHA0.1290.14918%0.16
EPA+DHA:AA ratio0.230.3235%0.044

NOTE: Erythrocyte phosholipids (PLs), plasma PLs and triacylglycerides (TAGs), and breast aspirate PLs and TAGs.

  • aBlood collected within a day of scheduled discontinuation of drug, after a nominal 6 months of intervention.

  • bSecond blood specimen collected on the day of the second aspiration, a median of 21 days after scheduled drug discontinuation.

  • cP-values <0.05 are indicated in bold.